= 62%; moderate certainty), with sustained effects at 3 months (SMD -0.61; 95% CI -0.81 to -0.41) and 6 months (SMD -0.49; 95% CI -0.71 to -0.27). Physical function also improved (SMD -0.69; 95% CI -0.87 to -0.51). Osteoarthritis demonstrated the largest effects, particularly knee OA (SMD -0.86). The most common adverse events were skin erythema (6.5%) and transient fatigue (4.8%), with no significant increase in serious adverse events (RR 0.98; 95% CI 0.61-1.58). Pelotherapy provides clinically meaningful and sustained reductions in pain and disability, with a generally favorable safety profile. Evidence is strongest for osteoarthritis, supporting its use as an adjunct in naturopathic and integrative medicine.
No takes yet. Share an insight, caveat, or question.
Balakrishna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: